MRI helpful for predicting uterine fibroids shrinkage after GnRH-agonist treatment

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802.

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802.

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802.